Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

New type of drug for drug-resistant cancer

New drug may be an effective alternative for patients whose cancer is resistant to currently available drugs.

4 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

UNMCC to investigate R-ketorolac use against ovarian cancer cells

Most drugs take ten years-and frequently, more-to go from concept to FDA approval. One way to reduce this time investment is to look for already-approved drugs that could be put to new uses. And that's just what Angela Wandinger-Ness, PhD, UNM Professor of Pathology, and Laurie Hudson, PhD, UNM Professor of Pharmaceutical Sciences, have done.

28 Sep 2012

MiR-214 plays a critical role in regulating ovarian cancer stem cell properties

Researchers at Moffitt Cancer Center have discovered that the micro ribonucleic acid miR-214 plays a critical role in regulating ovarian cancer stem cell properties. This knowledge, said the researchers, could pave the way for a therapeutic target for ovarian cancer.

28 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

Young women with BRCA mutations feel differently about options for relationships, careers

A study published in the October issue of the American Journal of Nursing (AJN) found that young women who learn they have BRCA1 and BRCA2 gene mutations felt differently about options for relationships, treatment, childbearing and careers.

26 Sep 2012

Researchers discover genetics secrets of ovarian cancer tumors

A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease.

25 Sep 2012

Molecular similarity between one sub-type of breast cancer and ovarian cancer

A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.

24 Sep 2012

Simple survey can effectively identify women with ovarian cancer symptoms

A simple three-question paper-and-pencil survey, given to women in the doctor's office in less than two minutes, can effectively identify those who are experiencing symptoms that may indicate ovarian cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center.

24 Sep 2012

Most basal-like breast and ovarian tumors have similar genetic origins

The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.

24 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

The p53 gene plays a key role in the prevention of cancer, by blocking cell growth and triggering programmed cell death or apoptosis. If, however, p53 has mutated and become defective, the cancer cells can acquire the ability to evade apoptosis and become more resistant to therapy.

20 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.

18 Sep 2012

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an investigational drug believed to hamper cancer cells.

15 Sep 2012

People with family history of certain diseases often underestimate their risk

People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.

13 Sep 2012

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.

13 Sep 2012

BRCA1/2 gene mutations lethal to human embryos

BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria.

13 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012